On September 29, WUXI BIO rose 3.28% in regular trading, trading at 55.45 HKD/share, with turnover of approximately 409 million HKD. The rally was driven by multiple catalysts sustaining positive momentum across the CXO sector.

On the earnings front, the company reported H1 revenue of 11.787 billion yuan, with gross margin improving from 42.7% to 46.2%. Operating cash flow surged 137.2% year-over-year to 4.287 billion yuan, while XDC external sales grew 37.8% YoY. Management raised full-year revenue growth guidance to 15%-18%. Several brokerages subsequently lifted their target prices to 60 HKD, maintaining buy ratings.

On the policy front, the national pharmaceutical industry development plan explicitly supports CDMO/CRO sectors, while AI-driven drug discovery commercialization expectations and strengthening China innovative drug overseas expansion narratives have further bolstered sentiment. Additionally, the company recently cancelled approximately 39.82 million repurchased shares, reinforcing shareholder returns.

Within the Life Sciences Tools & Services sector, peers also advanced broadly, with INSILICO up 4.65%, XTALPI up 3.4%, WUXI APPTEC up 3.3%, WUXI XDC up 1.14%, and GENSCRIPT BIO up 0.38%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)